Selective mTOR inhibition via FLCN drives TFE3-dependent VLDL-TG secretion and protects from MAFLD/MASH
The study identified a pathway that coordinates VLDL assembly and secretion regulated by non-canonical mTOR signaling. Targeting the pathway efficiently suppresses liver steatosis.